Proteasome inhibition: A new anti-inflammatory strategy

Journal of Molecular Medicine

Volumn 81, Issue 4, 2003, Pages 235-245

  Elliott, Peter J ^a   Zollner, Thomas Matthias ^b   Boehncke, Wolf Henning ^c  

^a Department of Preclinical Development and Formulations   (United States)

^b BAYER PHARMA AG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Asthma; Ischemia reperfusion injury; Nuclear factor kappa B; Psoriasis; Rheumatoid athritis

Indexed keywords

2 AMINOBENZYLSTATINE; 4 [3,3 DIMETHYL 2 (2 NAPHTHALEN 1 YLACETYLAMINO)BUTYRYLAMINO] 3 HYDROXY 5 PHENYL 2 (3,4,5 TRIMETHOXYBENZYLAMINO)PENTAOIC ACID [1 (2 HYDROXY 4 METHOXYBENZYLCARBAMOYL) 2 METHYLPROPYL]AMIDE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BMS 205820; BORONIC ACID DERIVATIVE; BORTEZOMIB; BUDESONIDE; CALPASTATIN; DEXAMETHASONE; EPONEMYCIN; EPOXOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MG 115; MG 262; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEASOME; PROTEASOME INHIBITOR; PS 1; PS 402; PYRROLIDINE DITHIOCARBAMATE; RITONAVIR; TISSUE PLASMINOGEN ACTIVATOR; UBIQUITIN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRAIN ISCHEMIA; CELL CYCLE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME MECHANISM; FATIGUE; FEVER; GENE EXPRESSION; HEART INFARCTION; HUMAN; IC 50; INFLAMMATION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACOPHORE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; RASH; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SCID MOUSE; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; XENOGRAFT;

EID: 0037569481     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-003-0422-2     Document Type: Review

References (82)

1. Ciechanover A (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 24:7151-7160
2. Peters JM, Harris JR, Finley D (eds) (1998) Ubiquitin and the biology of the cell. Plenum, New York
3. Rivett AJ (1993) Proteasomes: multicatalytic proteinase complexes. Biochem J 291:1-10
4. Goldberg AL, Stein R, Adams J (1995) New insights into proteasome function: from archaebacteria to drug development. Chem Biol 2:503-508
5. Hershko A (1997) Roles of ubiquitin-mediated proteolysis in cell cycle control Curr Opin Cell Biol 9:788-799
6. Epinat JC, Gilmore TD (1999) Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 18:6896-6909
7. Myung J, Kim KB, Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21:245-273
8. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739-758
9. Bogyo M, Wang EW (2002) Proteasome inhibitors: complex tools for a complex enzyme. Curr Top Microbiol Immunol 268:185-208
10. Vinitsky A, Michaud C, Powers JC, Orlowski M (1992) Inhibition of the chymotrypsin-like activity of the pituitary multi-catalytic proteinase complex. Biochemistry 31:9421-9428
11. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785
12. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771
13. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S (1996) Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem (Tokyo) 119:572-576
14. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL (1998) Potent and selective inhibitors of the proteasome: di-peptidyl boronic acids. Bioorg Med Chem Lett 8:333-338
15. Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116:637-646
16. Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7:9-16
17. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622
18. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The Proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076
19. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbattini P, Miller V, Hensley ML, Pezzulli S, Canales CA, Dauda A, Spriggs DR (2002) A phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2011
20. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine D-L, Elliott PJ, Pien CS, Guerciolini R, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427
21. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731
22. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin. J Biol Chem 271:7273-7276
23. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L, Stein RL (1997) Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272:182-188
24. Ostrowska H, Wojcik C, Omura S, Worowski K (1997) Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun 234:729-732
25. Geier E, Pfeifer G, Wilm M, Lucchiari-Hartz M, Baumeister W, Eichmann K, Niedermann G (1999) A giant protease with potential to substitute for some functions of the proteasome. Science 283:978-981
26. Soucy F, Grenier L, Behnke ML, Destree AT, McCormack TA, Adams J, Plamondon L (1999) A novel and efficient synthesis of a highly active analogue of clasto-lactacystin b-lactone. J Am Chem Soc 121:9967-9976
27. Groll M, Kim KB, Kairies N, Huber R, Crews CM (2000) Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of a',b'-epoxoketone proteasome inhibitors. J Am Chem Soc 122:1237-1238
28. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinfiammatory activity. Proc Natl Acad Sci USA 96:10403-10408
29. Furet P, Imbach P, Furst P, Lang M, Noorani M, Zimmermann J, Garcia-Echeverria C (2001) Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design. Bioorg Med Chem Lett 11:1321-1324
30. Furet P, Imbach P, Fuerst P, Lang M, Noorani M, Zimmermann J, Garcia-Echeverria C (2002) Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-Like activity of the human 20S proteasome. Bioorg Med Chem Lett 12:1331-1334
31. Garcia-Echeverria C, Imbach P, France D, Furst P, Lang M, Noorani AM, Scholz D, Zimmermann J, Furet P (2001) A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome. Bioorg Med Chem Lett 11:1317-1319
32. Lin ZP, Boller YC, Am SM, et al (1998) Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappa B activation in drug resistance. Cancer Res 58:3059-3065
33. Wang C-Y, Cusack JC, Liu R, et al (1999) Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-kappa B. Nat Med 5:412-417
34. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001) Possible role of NF-kappa B in the resolution of inflammation. Nat Med 7:1291-1297
35. Cheason BD (2002) Hematologic malignancies: new developments and future treatments. Semin Oncol 29:33-45
36. Almond JB, Cohen GM (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16:433-443
37. Jain KK (2000) Neuroprotection in cerebrovascular disease. Expert Opin Investig Drugs 9:695-711
38. White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, Grossman LI, Rafols JA, Krause GS (2000) Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 179-:1-33
39. Carroll JE, Hess DC, Howard EF, Hill WD (2000) Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury? Neuroreport 11:R1-R4
40. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC (2000) Proteasome inhibitor PS-519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 31:1686-1693
41. Berti R, Williams AJ, Moffett JR, Hale SL, Velarde LC, Elliott PJ, Yao C, Dave JR, Tortella FC (2002) Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. J Cereb Blood Flow Metab 22:1068-1079
42. Buchan AM, Li H, Blackburn B (1999) Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-κB activation. Neuroreport 11:427-430
43. Zhang L, Zhang ZG, Zhang RL, Chopp M, Adams J, Elliott PJ (2001) Postischemic (6 h) treatment with rht-PA and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32:2926-2931
44. Campbell B, Adams J, Shin YK, Lever AM (1999) Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31:467-476
45. Pye JP, Ardeshirpour F, McCain A, Bellinger DD, Merricks E, Adams J, Elliott PJ, Pien C, Fischer TH, Baldwin AS, Nichols TC (2002) Proteasome inhibition ablates activation of NF-kappaB induced during myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol (in press)
46. Bao J, Sato K, Li M, Gao Y, Abid R, Aird W, Simons M, Post MJ (2001) PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol 281:H2612-H2618
47. Baldwin AS (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649-683
48. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB (1998) Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95:15671-15676
49. Cromartie WJ, Craddock JC, Schwab JH, Anderie SK, Yang CH (1977) Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med 146:1585-1602
50. Migita K, Tanaka F, Yamasaki S, Shibatomi K, Ida H, Kawakami A, Aoyagi T, Kawabe Y, Eguchi K (2001) Regulation of rheumatoid synoviocyte proliferation by endogenous p53 induction. Clin Exp Immunol 126:334-338
51. Busse WW (1998) Inflammation in asthma: the cornerstone of the disease and target of therapy. J Allergy Clin Immunol 102:S17-S22
52. Montefort S, Holgate ST, Howarth PH (1993) Leukocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Respir J 6:1044-1054
53. Fujihara S, Ward C, Dransfield I, Hay RT, Uings IJ, Hayes B, Farrow SN, Haslett C, Rossi AG (2002) Inhibition of nuclear factor-kappaB activation un-masks the ability of TNF-alpha to induce human eosinophil apoptosis. Eur J Immunol 32:457-466
54. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J (1999) Proteasome inhibition: a novel mechanism to combat asthma. J Allergy Clin Immunol 104:294-300
55. Paterson PY, Swanborg RH (1988) Demyelinating diseases of the central nervous systems. In: Sampter M, Talmage DW, Frank MM, Austen KF, Claman HN (eds) Immunological diseases. Little Brown, Boston, pp 1877-1916
56. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Cano MC, Miller SD (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmunol 14:205-211
57. McRea BL, Vanderlugt CL, Dal Canto MC, Miller SD (1995) Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182:75-85
58. Hosseini H, Andre P, Lefevre N, Viala L, Walzer T, Peschanski M, Lotteau V (2001) Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. J Neuroimmunol 30:233-244
59. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L (1996) Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 16:145-149
60. Boehncke W-H (1996) Psoriasis and bacterial superantigens: formal or causal correlation? Trends Microbiol 4:485-48968
61. Robert C, Kupper TS (1999) Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 341:1817-1828
62. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke W-H (2002) Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 109:671-679
63. Boehncke W-H, Sterry W, Hainzl A, Scheffold W, Kaufmann R (1994) Psoriasiform architecture of murine epidermis overlying human psoriatic dermis transplanted onto SCID mice. Arch Dermatol Res 286:325-330
64. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM (1995) Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 146:580-588
65. Boehncke W-H, Kock M, Hardt-Weinelt K, Wolter M, Kaufmann R (1999) The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs. Arch Dermatol Res 291:104-106
66. Dam TM, Kang S, Nickoloff BJ, Voorhees JJ (1999) 1a,25-Dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted onto SCID mice. J Invest Dermatol 113:1082-1089
67. Goldberg AL, Rock K (2002) Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 8:338-340
68. Honda T, Yasutake K, Nihonmatsu N, Mercken M, Takahashi H, Murayama O, Murayama M, Sato K, Omori A, Tsubuki S, Saido TC, Takashima A (1999) Dual roles of proteasome in the metabolism of presenilin 1. J Neurochem 72:255-261
69. Hoffman EK, Wilcox HM, Scott RW, Siman R (1996) Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J Neurol Sc 139:15-20
70. Vives-Pi M, Vargas F, James RFL, Trowsdale J, Costa M, Sospedra M, Somoza N, Obiols G, Tampe R, Pujol-Borelli R (1997) Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity. Tissue Antigens 50:153-163
71. Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW, Read MA, Coggins MB, Solomon V, Goldberg AL, Brand SJ, Elliott PJ (1999) A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol 277:332-341
72. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ (2001) Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 61:3604-3609
73. Groettrup M, Schmidtke G (1999) Selective proteasome inhibitors: modulators of antigen presentation? DDT 4:63-70
74. Sirma H, Weil R, Rosmorduc O, Urban S, Israel A, Kremsdorf D, Brechot C (1998) Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene 16:2051-2063
75. Robek MD, Wieland SF, Chisari FV (2002) Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 76:3570-3574
76. Conner EM, Brand SJ, Davis JM, Kang DY, Grisham MB (1996) Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression. Inflamm Bowel Dis 2:133-147
77. Conner EM, Brand S, Davis JM, Laroux FS, Palombella VJ, Fuseler JW, Kang DY, Wolf RE, Grisham MB (1997) Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 282:1615-1622
78. Dijkstra G, Moshage H, Jansen PL (2002) Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl 236:37-41
79. Hasselgren PO, Fischer JE (1997) The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Ann Surg 225:307-316
80. Snyder JG, Prewitt R, Campsen J, Britt LD (2002) PDTC and MG-132, inhibitors of NF-kappaB, block endotoxin induced vasodilatation of isolated rat skeletal muscle arterioles. Shock 17:304-307
81. Feist E, Dorner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, Burmester GR, Kloetzel PM (1996) Proteasome a-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 10:1313-1318
82. Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM (1999) Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha, "beta"-epoxyketones. Chem Biol 6:811-822